2. GPCR/G Protein Neuronal Signaling
  3. mGluR
  4. Basimglurant

Basimglurant  (Synonyms: RG7090; RO4917523)

Cat. No.: HY-15446 Purity: 98.0%
COA
SDS
Handling Instructions Technical Support

Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [3H]-ABP688 (HY-110141)) and 35.6 nM (against [3H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc.

For research use only. We do not sell to patients.

Basimglurant

Basimglurant Chemical Structure

CAS No. : 802906-73-6

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Basimglurant:

Basimglurant Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Basimglurant

View All mGluR Isoform Specific Products:

View All Isoforms
mGluR1 mGluR2 mGluR3 mGluR4 mGluR5 mGluR6 mGluR7 mGluR8 mGluR

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [3H]-ABP688 (HY-110141)) and 35.6 nM (against [3H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc[1][2].

IC50 & Target[1]

mGlu5 Receptor

1.1 nM (Kd)

Cellular Effect
Cell Line Type Value Description References
HEK293 IC50
7 nM
Compound: 2
Negative allosteric modulation of mGlu5 (unknown origin) expressed in HEK293 cells assessed as inhibition of L-AP4-induced calcium mobilization incubated for 30 mins prior to L-AP4 induction by Fluo-4 AM staining-based fluorescence assay
Negative allosteric modulation of mGlu5 (unknown origin) expressed in HEK293 cells assessed as inhibition of L-AP4-induced calcium mobilization incubated for 30 mins prior to L-AP4 induction by Fluo-4 AM staining-based fluorescence assay
[PMID: 25565255]
In Vitro

Basimglurant shows low metabolic stability in rat liver microsomes (11 μL/min/mg) and good stability in human liver microsomes (CL <10 μL/min/mg)[1].
Basimglurant shows no teratogenic potential in embryonic stem cell assays[1].
Basimglurant potently inhibits the binding of [3H]-MPEP to human, mouse and rat mGlu5 receptors, with Ki values of 35.6 nM, 29.5 nM and 33.2 nM for the three receptors, respectively[2].
Basimglurant potently inhibits Quisqualate-induced calcium mobilization in human, mouse, and rat mGlu5-expressing HEK293 cells, with IC50 values of 7.0 nM, 8.88 nM, and 7.48 nM, respectively[2].
Basimglurant potently inhibits Quisqualate-induced IP accumulation in HEK293 cells expressing human, mouse, and rat mGlu5, with IC50 values of 5.85 nM, 4.98 nM, and 5.93 nM, respectively. It also acts as an inverse agonist of the human mGlu5 receptor, with a corresponding IC50 of 38.1 nM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Basimglurant Related Antibodies
In Vivo

Basimglurant (1-3 mg/kg; i.p., once daily for 21 consecutive days) exhibits significant antidepressant-like activity in rats with anhedonia induced by chronic mild stress[2].
Basimglurant (10-30 mg/kg; p.o.; administered three times within 24 h) exerts antidepressant-like effects in the forced swimming test in rats[2].
Basimglurant (1-30 mg/kg; p.o.; single administration) induces a brain activity pattern highly similar to that of typical antidepressants in rats[2].
Basimglurant (0.03-0.3 mg/kg; p.o.; single administration) exhibits anxiolytic-like activity in the rat Vogel conflict test[2].
Basimglurant (0.01-1 mg/kg; p.o.; single administration) exerts anxiolytic effects in a mouse model of stress-induced hyperthermia[2].
Basimglurant (0.3-1 mg/kg; p.o.; single administration) exhibits anxiolytic-like activity in the rat conditioned emotional response test[2].
Basimglurant (0.1-1 mg/kg; p.o.; single administration) produces anxiolytic-like effects in the fear-potentiated startle test in rats[2].
Basimglurant (10 mg/kg; p.o.; single administration) exhibits analgesic activity in the late phase of the formalin-induced pain model in mice[2].
Basimglurant (0.1-10 mg/kg; subcutaneous injection; single administration) dose-dependently inhibits cold allodynia in rats with sciatic nerve ligation[2].
Basimglurant (0.03-0.3 mg/kg; intravenous administration; single dose) dose-dependently increases the micturition threshold volume in anesthetized rats[2].
Basimglurant (0.01-0.03 mg/kg; intravenous injection; single administration) potently reduces the bladder contraction frequency in anesthetized rats[2].
Basimglurant (0.03-0.3 mg/kg; p.o.; once daily; for 5 consecutive days) exerts a dose-dependent arousal-promoting effect during the active dark phase of Norwegian rats, reduces rapid eye movement (REM) sleep and non-rapid eye movement (non-REM) sleep, prolongs sleep latency, and enhances the δ-wave power of non-REM sleep[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation)[2]
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.; daily; 21 days
Result: Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels.
Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg.
Had no significant effect on anhedonia index in unstressed rats.
Animal Model: Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation)[2]
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.; daily; 21 days
Result: Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels.
Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg.
Had no significant effect on anhedonia index in unstressed rats.
Animal Model: Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model)[2]
Dosage: 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle.
Animal Model: Fischer F344 rats (male, ~250 g, fMRI-based brain activity profiling model)[2]
Dosage: 1 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 1 hour pre-fMRI imaging
Result: Increased perfusion in the dorsal striatum and decreased perfusion in the medial prefrontal cortex, dorsal hippocampus, thalamus, hypothalamus, septum, nucleus accumbens, ventral pallidum, and entorhinal piriform cortex at 1 mg/kg.
Amplified the perfusion changes observed at 1 mg/kg at 10 mg/kg.
Showed a pattern match coefficient (PMC) of >0.71 compared to prototypical antidepressants including duloxetine, reboxetine, imipramine, bupropion, and electroconvulsive treatment (ECT) at 1 and 10 mg/kg.
Surpassed the root mean square (RMS) response strength of ECT and standard antidepressants at 30 mg/kg at 1 and 10 mg/kg.
Animal Model: Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model)[2]
Dosage: 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle.
Animal Model: NMRI mice (male, ~22 g, stress-induced hyperthermia model)[2]
Dosage: 1 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Reduced stress-induced hyperthermia by -48% at 0.01 mg/kg, -73% at 0.1 mg/kg, and -145% at 1 mg/kg compared to vehicle, with all doses producing significant effects.
Animal Model: Sprague Dawley rats (male, 350 g, conditioned emotional response model)[2]
Dosage: 0.03 mg/kg; 0.1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased the suppression ratio by +567% at 0.3 mg/kg and +583% at 1 mg/kg compared to vehicle, indicating reduced fear response.
Animal Model: Sprague Dawley rats (male, 225-287 g, fear-potentiated startle model)[2]
Dosage: 0.03 mg/kg; 0.1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Reduced fear-potentiated startle amplitude by -53% at 0.1 mg/kg and -94% at 1 mg/kg compared to vehicle, with significant effects at both doses.
Animal Model: NMRI mice (male, 24-30 g, formalin-induced paw licking model, late phase)[2]
Dosage: 1 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 40 minutes pre-formalin injection
Result: Reduced paw licking time by -91% (non-significant) at 1 mg/kg and -95% (significant) at 10 mg/kg compared to vehicle in the late phase of formalin-induced pain.
Had no significant effect in the early phase at any tested dose.
Animal Model: Sprague Dawley rats (female, 100-250 g, Bennett model of cold allodynia with sciatic nerve constriction injury)[2]
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: s.c.; single dose; 60 minutes pre-test
Result: Increased the inhibition rate of cold allodynia by 28% at 0.1 mg/kg, 37% at 0.3 mg/kg, 50% at 1 mg/kg, 39% at 3 mg/kg, and 58% at 10 mg/kg compared to vehicle.
Produced significant effects at all doses, with maximal efficacy comparable to morphine (64% inhibition rate) and duloxetine (56% inhibition rate).
Animal Model: Sprague Dawley rats (female, 200-250 g, volume-induced micturition reflex model with cannulated bladders, anesthetized)[2]
Dosage: 0.03 mg/kg; 0.3 mg/kg
Administration: i.v.; single dose
Result: Increased the micturition threshold volume by +27% at 0.03 mg/kg and +166.9% at 0.3 mg/kg compared to baseline, with significant effects at both doses.
Animal Model: Sprague Dawley rats (female, 200-250 g, isovolumetric bladder contraction model with cannulated bladders, anesthetized)[2]
Dosage: 0.01 mg/kg; 0.03 mg/kg
Administration: i.v.; single dose
Result: Reduced bladder contraction frequency by -88.5% at 0.01 mg/kg and -79.9% at 0.03 mg/kg compared to vehicle, with maximal effects comparable at both doses.
Clinical Trial
Molecular Weight

325.77

Formula

C18H13ClFN3
CAS No.
Appearance

Solid

Color

Off-white to yellow

SMILES

CC1=C(C#CC2=CC(Cl)=NC=C2)N=C(C)N1C3=CC=C(F)C=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 33.33 mg/mL (102.31 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.0697 mL 15.3483 mL 30.6965 mL
5 mM 0.6139 mL 3.0697 mL 6.1393 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.67 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (7.67 mM); Suspended solution; Need ultrasonic and warming

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.0697 mL 15.3483 mL 30.6965 mL 76.7413 mL
5 mM 0.6139 mL 3.0697 mL 6.1393 mL 15.3483 mL
10 mM 0.3070 mL 1.5348 mL 3.0697 mL 7.6741 mL
15 mM 0.2046 mL 1.0232 mL 2.0464 mL 5.1161 mL
20 mM 0.1535 mL 0.7674 mL 1.5348 mL 3.8371 mL
25 mM 0.1228 mL 0.6139 mL 1.2279 mL 3.0697 mL
30 mM 0.1023 mL 0.5116 mL 1.0232 mL 2.5580 mL
40 mM 0.0767 mL 0.3837 mL 0.7674 mL 1.9185 mL
50 mM 0.0614 mL 0.3070 mL 0.6139 mL 1.5348 mL
60 mM 0.0512 mL 0.2558 mL 0.5116 mL 1.2790 mL
80 mM 0.0384 mL 0.1919 mL 0.3837 mL 0.9593 mL
100 mM 0.0307 mL 0.1535 mL 0.3070 mL 0.7674 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Basimglurant Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Basimglurant802906-73-6RG7090 RO4917523RG 7090RG-7090RO4917523RO 4917523RO-4917523mGluRMetabotropic glutamate receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Basimglurant
Cat. No.:
HY-15446
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.